Peptide Safety: Adverse Events, Contamination and Injection Risks

Urgent first

Trouble breathing, swelling of the face or throat, fainting or severe symptoms after any injection are an emergency. In the United States, call 911. This page is education only and gives no instructions for injecting or preparing any product.

Safety Concerns

Evidence labels used here: approved medicine, preclinical (cells/animals only), insufficient evidence and evidence of harm.

Injection bypasses the body's defenses. FDA notes that injectable products are delivered directly into the body, sometimes into the bloodstream, which can pose risks of serious harm. [1]

Immune reactions. Synthetic peptides and their impurities can trigger unwanted immune responses. [2] Even an approved peptide shows this: in tesamorelin trials, anti-drug antibodies were detected in about half of treated patients, and the label lists hypersensitivity reactions and injection-site reactions. [3] FDA's compounding page flags immunogenicity (immune response) risk for many unapproved peptides, along with impurities and difficulty characterizing the active ingredient. [4]

Specific signals FDA describes. For CJC-1295, FDA identified serious adverse events including increased heart rate and a systemic vasodilatory reaction. [4] For ipamorelin, a published study reported serious adverse events including death when it was given intravenously to improve gastric motility. [4] For ibutamoren (a small-molecule drug that acts on the same hormone system), a trial in hip fracture patients ended early over a potential congestive heart failure signal. [4][5] For GHRP-6, FDA cites possible effects on cortisol and blood glucose. [4] For thymosin beta-4 fragment (TB-500) and Semax or Selank, FDA says it lacks the information needed to know whether they would cause harm in humans. [4]

Product quality. Compounded drugs that are contaminated or contain too much active ingredient can cause serious injury or death. [6] In a study of semaglutide bought from illegal online sellers, all purchased vials were judged probable substandard or falsified products, endotoxin was detected in every sample, and measured purity was 7.7% to 14.37% against a 99% label claim. [7] That study tested semaglutide, not the peptides in this section, but it shows what unregulated supply can look like. FDA warns that products that avoid regulatory safeguards may be contaminated, counterfeit, or contain different ingredients altogether. [8]

Clinical Evidence

Human studies of these peptides are mostly small and short.

Reading across these: "well tolerated" in a short trial is not proof of long-term safety, and a hormone level changing is not a health benefit. A 2026 review concluded that clinical adoption of injectable peptides has outpaced high-quality evidence, that regenerative and growth-hormone-axis peptides remain investigational with uncertain safety, and that product quality is a concern. [12]

Who should be especially careful

The tesamorelin label shows what a hormone-acting peptide can require. It is contraindicated in pregnancy and in people with active cancer, can cause glucose intolerance, and may speed growth in children with open growth plates. [3] Unapproved products have no such label. Anyone who is pregnant, has or had cancer, has diabetes or prediabetes, or is a child or teen should talk with a clinician before any hormone-acting product.

What to do

Report problems to a clinician and see side effects and reporting. General quality issues are covered in product quality and contamination. For how categories differ, see approved, investigational and unapproved peptides.